Sir, The extended-spectrum cephalosporins are the antibiotics of choice for the treatment of complicated infections caused by Enterobacteriaceae. However, in the last few years the number of extended-spectrum b-lactamase (ESBL)-producing isolates has increased in Europe, threatening the efficacy of therapy. 1 Resistant isolates are mainly of human origin, but the frequency of ESBL-producing enterobacteria of animal origin is also increasing. 1 Among zoonotic pathogens with clinical relevance in human medicine, Salmonella enterica subsp. enterica serovar Typhimurium 4, [5] ,12:i:-has become increasingly important since the mid-1990s. Currently this serovar, designated as the monophasic variant of Salmonella Typhimurium, ranks among the 10 most common serovars isolated from humans in several European countries. 2 Most of the isolates are resistant to ampicillin, streptomycin, sulphonamides and tetracyclines. They have been implicated in several outbreaks, sometimes associated with severe disease. 2 -4 The sources of these infections have turned out to be mainly pigs and pork products. 2 -4 The National Salmonella Reference Laboratory (NRL-Salm) of the German Federal Institute for Risk Assessment (BfR) receives Salmonella strains isolated in all Federal States of Germany, originating from routine surveys of different investigation centres involved in public health or from national or European Union (EU) monitoring programmes. During 2003-10 a total of 31839 German Salmonella isolates [2237 (7%) serotyped as monophasic Salmonella Typhimurium 4, [5] ,12:i:-] were collected. These 31839 isolates originated from food-producing animals (38%), food (29%), non-food-producing animals (15.5%), feed (3.5%), environment (5.5%), humans (0.5%) and other sources (8%). By broth microdilution (using CLSI documents M7-A8 and M100-S21), only 160 isolates (0.5%) showed MIC values ≥4 mg/L for cefotaxime and/or ceftazidime or ceftiofur, suggesting the presence of ESBLs or AmpC enzymes. Most of these isolates belonged to serotype Salmonella Paratyphi B d-tartrate+ (33 isolates), Salmonella Typhimurium (28), Salmonella Saintpaul (23) and, interestingly, to monophasic Salmonella Typhimurium (16, representing 10% of the putative ESBL-positive strains). These 16 isolates were isolated between 2007 and 2011 in five different German Federal States and from different animals (swine, cattle, sheep and an unspecified avian source; Table 1 ). In some cases, more than one isolate coincided in the isolation place, date, phage type and antimicrobial resistance pattern (Table 1) , making their epidemiological linkage very likely (duplicates).
All isolates were tested against a panel of 15 b-lactams (Oxoid, Wesel, Germany) including penicillins, first-through to fourth-generation cephalosporins, cephamycins, monobactams, carbapenems and b-lactamase inhibitors, by the CLSI disc diffusion method (CLSI documents M2-A10 and M100-S21). Characterizations of resistance genes including b-lactamase encoding genes (bla TEM , bla OXA , bla CARB , bla CTX , bla SHV , bla ACC , bla CIT , bla DHA , bla EBC , bla FOX and bla MOX ) and class 1 and 2 integrons by PCR-amplification/sequencing, as well as, for selected isolates, isoelectrofocusing of the b-lactamases, were conducted. 5 All isolates were also typed by XbaI-PFGE analysis (www.pulsenetinternational.org).
After these preliminary analyses, nine isolates (representative of all its duplicates) were considered as type strains (Table 1) and were further analysed by molecular methods. They were typed by multilocus variable-number tandem repeat analysis (MLVA) and S1-nuclease-PFGE plasmid-profiling. 3 -5 The incompatibility group of their plasmids was determined by a PCR-based replicon typing (PBRT) method. 6 Plasmid DNA was hybridized with specific bla-and rep-probes ( Figure S1 , available as Supplementary data at JAC Online). 5 The nine type strains showed different resistance phenotypes and genotypes (Table 1) , but all of them were resistant to sulfadiazine and tetracycline, encoded by the genes sul2 and tet(B) in all cases, and additionally by sul1 and tet(A) in three of them. Most of the strains also showed resistance to streptomycin and trimethoprim, which in three cases were associated with the presence of a class 1 integron. Two isolates harboured an integron carrying the dfrA1 and aadA1 gene cassettes (PCR-variable region of 1586 bp using 5 ′ CS-3 ′ CS primers) 7 , and one isolate harboured an integron containing aadA1 (PCRvariable region of 1009 bp). Both integrons, known as In18 and In2 (http://integrall.bio.ua.pt/), have been frequently found in several Salmonella serovars. 7 No class 2 integrons were detected. The type strains showed six XbaI-PFGE profiles and seven MLVA types (Table 1) , most of them present in isolates ascribed to the European monophasic Salmonella Typhimurium clone. 2 -4 Only 09-02658 and 09-02695 shared identical resistancephenotype/genotype, phage type, XbaI-PFGE and MLVA profiles (Table 1) , indicating a clonal relationship between these two type strains, despite their different origin and place of isolation.
Other type strains such as 09-04283 and 10-04914 (different year, same origin and region), or 10-00943 and 10-04691 (different year and region, same origin) only differed in highly variable loci analysed by MLVA.
With regard to b-lactams, the nine type strains shared the resistance phenotype ampicillin/cefalotin/cefuroxime/ticarcillin/ piperacillin/ceftiofur/ceftriaxone/cefotaxime/aztreonam I /cefopodoxime with some variations in the susceptibility to cefepime (Table 1) . Eight of the nine strains expressed the ESBL CTX-M-1 (isoelectric point, pI ¼ 8.9), five of them together with the narrowspectrum b-lactamase TEM-1 (pI¼ 5.4). In Germany and other European countries, CTX-M-1 enzymes are most frequently found in Salmonella isolates of human and animal origin. 1, 5, 8 In all cases, the bla CTX-M-1 gene was located on plasmids ranging in size from 35 to .100 kb (Table 1, Figure S1 ). The ESBL-encoding plasmids belonged to the incompatibility group IncI1 in all type strains except 07-01535, in which the plasmid (of 35 kb) was ascribed to the IncN group (Table 1, Figure S1 ). IncI1 and IncN plasmids are commonly associated with the transfer of ESBL genes like bla CTX-M-1 , which are frequently detected in Escherichia coli and Salmonella enterica isolates of human and animal origin in Europe. 1, 5, 8 The only strain of avian origin (10-01503) showed a PFGE pattern clearly different from all other isolates ( Figure S1 ). This isolate produced CTX-M-2 (pI ¼7.9). The corresponding bla gene was located on a 275 kb plasmid whose Inc group could not be characterized with the scheme used.
6 CTX-M-2 has been associated with poultry in different European countries. 1, 8 In fact, it has been often found located on HI2 or I1 plasmids in German Salmonella Paratyphi B d-tartrate+ analysed in our laboratories (B. Guerra, unpublished observations).
As far as we know, this is the first report of the presence of ESBLs in monophasic Salmonella Typhimurium isolates from Germany. Their emergence seems to be mainly based on the spread, during recent years, of isolates belonging to the predominant European monophasic Salmonella Typhimurium clone, which acquired different IncI1 plasmids harbouring the bla CTX-M-1 gene, within different food-producing animals (mainly swine, but also other sources like cattle and sheep). Owing to the current public health and epidemiological relevance of the European monophasic Salmonella Typhimurium clone, 2 -4 and the appearance and spread within different animal species of new variants combining clones/plasmids/b-lactamases (like the CTX-M2 avian isolate), the data described here are a cause for concern and deserve further surveillance and mitigation strategies.
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Research letters
Sir, Telavancin is a lipoglycopeptide antibiotic with a chemical structure closely related to the glycopeptide antibiotic vancomycin.
Telavancin has excellent in vitro activity against methicillinresistant staphylococci and, in the trials which led to its approval for the treatment of skin and soft tissue infections, it was shown to be non-inferior to vancomycin. 1 Renal toxicity is the principal significant adverse effect of telavancin.
2 A standard dose of 10 mg/kg daily is recommended in patients with normal renal function and monitoring of serum or plasma levels is neither recommended nor available commercially. 2 It is not known if telavancin serum levels correlate with the efficacy or renal toxicity of this antibiotic. Perhaps due to a lack of therapeutic superiority data and concerns about renal toxicity, telavancin has yet to be widely used in clinical practice.
Recently, a patient receiving the standard dose of telavancin for a staphylococcal infection was demonstrated to have an apparent detectable serum vancomycin level (after the level was inadvertently ordered by a house officer). This serendipitous finding led us to check vancomycin levels in several other patients with normal renal function who were receiving standard doses of telavancin. No patients had received vancomycin. Trough levels were obtained immediately prior to a dose of telavancin and peak levels were obtained 1 h after the infusion was completed. The vancomycin serum levels were determined by a particle-enhanced turbidometric inhibition immunoassay method (Synchron LX System, Beckman Coulter, Inc., Brea, CA, USA). The results are shown in Table 1 .
We speculate that if a consistent correlation can be established between serum vancomycin and telavancin levels in patients treated with telavancin, a commercially available vancomycin serum level assay can then be used to monitor telavancin therapy, in place of an unavailable telavancin assay, in order to establish possible correlation between telavancin levels and its clinical efficacy and/or renal toxicity. Although telavancin plasma assays were apparently done as part of approval studies, we had no access to a telavancin assay to attempt to establish the correlation. 3 If the manufacturer of telavancin or an independent investigator is able to perform telavancin assays, they may choose to perform such a study.
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